Oneness Biotech Co Ltd (4743) - Net Assets
Based on the latest financial reports, Oneness Biotech Co Ltd (4743) has net assets worth NT$10.97 Billion TWD (≈ $345.50 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$11.84 Billion ≈ $372.98 Million USD) and total liabilities (NT$872.39 Million ≈ $27.49 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Oneness Biotech Co Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$10.97 Billion |
| % of Total Assets | 92.63% |
| Annual Growth Rate | 17.73% |
| 5-Year Change | -6.97% |
| 10-Year Change | 362.83% |
| Growth Volatility | 55.66 |
Oneness Biotech Co Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Oneness Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Oneness Biotech Co Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Oneness Biotech Co Ltd (2009–2024)
The table below shows the annual net assets of Oneness Biotech Co Ltd from 2009 to 2024. For live valuation and market cap data, see market cap of Oneness Biotech Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$12.80 Billion ≈ $403.27 Million |
-11.71% |
| 2023-12-31 | NT$14.50 Billion ≈ $456.74 Million |
-2.57% |
| 2022-12-31 | NT$14.88 Billion ≈ $468.80 Million |
+5.61% |
| 2021-12-31 | NT$14.09 Billion ≈ $443.89 Million |
+2.40% |
| 2020-12-31 | NT$13.76 Billion ≈ $433.50 Million |
+113.04% |
| 2019-12-31 | NT$6.46 Billion ≈ $203.48 Million |
+198.22% |
| 2018-12-31 | NT$2.17 Billion ≈ $68.23 Million |
-13.19% |
| 2017-12-31 | NT$2.49 Billion ≈ $78.60 Million |
-1.16% |
| 2016-12-31 | NT$2.52 Billion ≈ $79.53 Million |
-8.73% |
| 2015-12-31 | NT$2.77 Billion ≈ $87.13 Million |
+42.96% |
| 2014-12-31 | NT$1.93 Billion ≈ $60.95 Million |
-1.61% |
| 2013-12-31 | NT$1.97 Billion ≈ $61.94 Million |
+39.97% |
| 2012-12-31 | NT$1.40 Billion ≈ $44.26 Million |
+2.75% |
| 2011-12-31 | NT$1.37 Billion ≈ $43.07 Million |
+25.53% |
| 2010-12-31 | NT$1.09 Billion ≈ $34.31 Million |
-1.57% |
| 2009-12-31 | NT$1.11 Billion ≈ $34.86 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oneness Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8007.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$13.45 Billion | 109.38% |
| Total Equity | NT$12.30 Billion | 100.00% |
Oneness Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Oneness Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Boozt AB
ST:BOOZT
|
$778.03 Million |
|
Ningbo Sinyuan ZM Technology Co. Ltd. A
SHE:301398
|
$778.16 Million |
|
Shanghai Shuixing Home Textile Co Ltd Class A
SHG:603365
|
$778.22 Million |
|
Cromwell Property Group
AU:CMW
|
$778.27 Million |
|
Banco Mercantil do Brasil S.A
SA:BMEB3
|
$777.63 Million |
|
Cita Mineral Investindo Tbk PT
JK:CITA
|
$777.41 Million |
|
SERVICE STREAM LTD
F:UFY
|
$777.15 Million |
|
IRESS LTD
F:BRF
|
$777.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oneness Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,053,205,000 to 12,298,878,000, a change of -1,754,327,000 (-12.5%).
- Net loss of 1,165,147,000 reduced equity.
- New share issuances of 54,910,000 increased equity.
- Other comprehensive income decreased equity by 1,834,250,000.
- Other factors increased equity by 1,190,160,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-1.17 Billion | -9.47% |
| Share Issuances | NT$54.91 Million | +0.45% |
| Other Comprehensive Income | NT$-1.83 Billion | -14.91% |
| Other Changes | NT$1.19 Billion | +9.68% |
| Total Change | NT$- | -12.48% |
Book Value vs Market Value Analysis
This analysis compares Oneness Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.52x to 2.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$11.41 | NT$51.60 | x |
| 2010-12-31 | NT$6.22 | NT$51.60 | x |
| 2011-12-31 | NT$7.58 | NT$51.60 | x |
| 2012-12-31 | NT$7.22 | NT$51.60 | x |
| 2013-12-31 | NT$9.98 | NT$51.60 | x |
| 2014-12-31 | NT$10.08 | NT$51.60 | x |
| 2015-12-31 | NT$12.94 | NT$51.60 | x |
| 2016-12-31 | NT$11.34 | NT$51.60 | x |
| 2017-12-31 | NT$10.52 | NT$51.60 | x |
| 2018-12-31 | NT$9.08 | NT$51.60 | x |
| 2019-12-31 | NT$22.14 | NT$51.60 | x |
| 2020-12-31 | NT$33.58 | NT$51.60 | x |
| 2021-12-31 | NT$32.32 | NT$51.60 | x |
| 2022-12-31 | NT$32.63 | NT$51.60 | x |
| 2023-12-31 | NT$29.69 | NT$51.60 | x |
| 2024-12-31 | NT$25.73 | NT$51.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oneness Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -988.03%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.11x
- Recent ROE (-9.47%) is below the historical average (-1.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.57% | 385.04% | 0.00x | 1.01x | NT$-104.37 Million |
| 2010 | 0.09% | 1.61% | 0.05x | 1.02x | NT$-107.95 Million |
| 2011 | 1.02% | 375.67% | 0.00x | 1.01x | NT$-122.76 Million |
| 2012 | -1.95% | -318.60% | 0.01x | 1.02x | NT$-167.86 Million |
| 2013 | 14.05% | 5993.77% | 0.00x | 1.06x | NT$79.64 Million |
| 2014 | 10.32% | 3645.30% | 0.00x | 1.04x | NT$6.27 Million |
| 2015 | -3.36% | -1186.29% | 0.00x | 1.02x | NT$-369.58 Million |
| 2016 | -0.56% | -249.99% | 0.00x | 1.01x | NT$-266.68 Million |
| 2017 | -6.62% | -6008.74% | 0.00x | 1.07x | NT$-390.31 Million |
| 2018 | -11.60% | -1248.60% | 0.01x | 1.15x | NT$-438.43 Million |
| 2019 | -5.19% | -2437.57% | 0.00x | 1.10x | NT$-961.12 Million |
| 2020 | -1.85% | -604.92% | 0.00x | 1.13x | NT$-1.61 Billion |
| 2021 | -2.95% | -627.72% | 0.00x | 1.12x | NT$-1.81 Billion |
| 2022 | 2.46% | 33.78% | 0.07x | 1.07x | NT$-1.10 Billion |
| 2023 | -9.34% | -1512.82% | 0.01x | 1.09x | NT$-2.72 Billion |
| 2024 | -9.47% | -988.03% | 0.01x | 1.11x | NT$-2.40 Billion |
Industry Comparison
This section compares Oneness Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,718,491,500
- Average return on equity (ROE) among peers: 5.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oneness Biotech Co Ltd (4743) | NT$10.97 Billion | 0.57% | 0.08x | $777.76 Million |
| Apex Biotechnology Corp (1733) | $1.26 Billion | 22.49% | 0.17x | $89.27 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.64 Billion | 9.45% | 0.73x | $183.66 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $173.96 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.77 Billion | 3.40% | 0.54x | $93.90 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.16 Billion | 13.75% | 0.60x | $101.01 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $34.56 Million |
| GenMont Biotech Inc (3164) | $1.50 Billion | 3.81% | 0.13x | $47.15 Million |
| Medigen Biotechnology (3176) | $6.47 Billion | -10.44% | 0.54x | $145.05 Million |
| Sagittarius Life Science (3205) | $588.38 Million | -12.60% | 0.26x | $120.02 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.41 Billion | -0.87% | 0.11x | $97.48 Million |
About Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II… Read more